Literature DB >> 18273568

Management of acute myocardial infarction in the real world: a summary report from The Ami-Florence Italian Registry.

Daniela Balzi1, Alessandro Barchielli, Giovanni Maria Santoro, Nazario Carrabba, Eva Buiatti, Cristina Giglioli, Serafina Valente, Giorgio Baldereschi, Laura Del Bianco, Matteo Monami, Gian Franco Gensini, Niccolò Marchionni.   

Abstract

The Florence Acute Myocardial Infarction registry was a population-based, prospective study aimed at identifying the determinants of coronary reperfusion therapy [CRT, by primary coronary intervention (PCI) in more than 95% of cases] utilization and of prognosis in patients with ST-segment elevation myocardial infarction (STEMI). The registry involved one teaching hospital with, and five district hospitals without PCI facilities. Overall, as many as 45.6% of 930 cases of STEMI did not receive any form of CRT. In multivariable analysis, the direct admission to the teaching hospital was the strongest positive predictor, whereas the time delay, older age, and chronic comorbid conditions were negative predictors of CRT utilization. Compared to conservative therapy, CRT was associated with a remarkably reduced 12-month mortality, after adjusting for age, chronic comorbidities and Killip class, which also were significantly associated with long-term prognosis. The higher crude mortality observed in women was accounted for by older age and other age-related factors. The improvement in prognosis with CRT was larger in older patients and/or in those with a greater burden of chronic comorbidity, who less frequently received CRT. These results suggest the need for interdisciplinary reassessing the adherence to therapeutic guidelines and the criteria adopted in the real clinical world to select patients for CRT during STEMI.

Entities:  

Mesh:

Year:  2008        PMID: 18273568     DOI: 10.1007/s11739-008-0090-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  18 in total

1.  1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).

Authors:  T J Ryan; E M Antman; N H Brooks; R M Califf; L D Hillis; L F Hiratzka; E Rapaport; B Riegel; R O Russell; E E Smith; W D Weaver; R J Gibbons; J S Alpert; K A Eagle; T J Gardner; A Garson; G Gregoratos; S C Smith
Journal:  Circulation       Date:  1999-08-31       Impact factor: 29.690

Review 2.  Primary coronary intervention for acute myocardial infarction.

Authors:  Ellen C Keeley; Cindy L Grines
Journal:  JAMA       Date:  2004-02-11       Impact factor: 56.272

3.  Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction.

Authors:  Daniela Balzi; Alessandro Barchielli; Eva Buiatti; Caterina Franceschini; Rinaldo Lavecchia; Matteo Monami; Giovanni Maria Santoro; Nazario Carrabba; Massimo Margheri; Iacopo Olivotto; Gian Franco Gensini; Niccolò Marchionni
Journal:  Am Heart J       Date:  2006-05       Impact factor: 4.749

4.  Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE).

Authors:  K F Carruthers; O H Dabbous; M D Flather; I Starkey; A Jacob; D Macleod; K A A Fox
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

5.  Do we practice geriatric cardiology?

Authors:  W W Parmley
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

6.  Social inequalities in male mortality amenable to medical intervention in British Columbia.

Authors:  E Wood; A M Sallar; M T Schechter; R S Hogg
Journal:  Soc Sci Med       Date:  1999-06       Impact factor: 4.634

7.  Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.

Authors:  H V Barron; L J Bowlby; T Breen; W J Rogers; J G Canto; Y Zhang; A J Tiefenbrunn; W D Weaver
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

8.  Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy: results of the acute myocardial infarction Florence registry (AMI-Florence).

Authors:  Eva Buiatti; Alessandro Barchielli; Niccolò Marchionni; Daniela Balzi; Nazario Carrabba; Serafina Valente; Iacopo Olivotto; Cristina Landini; Maurizio Filice; Marco Torri; Giuseppe Regoli; Giovanni M Santoro
Journal:  Eur Heart J       Date:  2003-07       Impact factor: 29.983

Review 9.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

10.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

View more
  8 in total

1.  Should we improve the management of NSTEMI? Results from the population-based "acute myocardial infarction in Florence 2" (AMI-Florence 2) registry.

Authors:  Daniela Balzi; Mauro Di Bari; Alessandro Barchielli; Piercarlo Ballo; Nazario Carrabba; Antonella Cordisco; Maria Cristina Landini; Giovanni Maria Santoro; Serafina Valente; Alfredo Zuppiroli; Niccolò Marchionni; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2012-07-10       Impact factor: 3.397

2.  Left ventricular remodeling in the elderly with acute anterior myocardial infarction treated with primary coronary intervention.

Authors:  Francesca Innocenti; Francesca Caldi; Cinzia Meini; Chiara Agresti; Giorgio J Baldereschi; Niccolò Marchionni; Giulio Masotti; Riccardo Pini
Journal:  Intern Emerg Med       Date:  2010-07-17       Impact factor: 3.397

3.  STEMI management: trials, registries, and the real world.

Authors:  Giovanni Melandri; Franco Semprini; Samuele Nanni; Daniela Calabrese; Fabio Vagnarelli; Angelo Branzi
Journal:  Intern Emerg Med       Date:  2008-06       Impact factor: 3.397

4.  When you hear hoofbeats, think of horses and zebras: a 58-year-old man with chest pain and palpitations.

Authors:  Bartosz Hudzik; Janusz Szkodzinski; Aleksandra Wozniak; Alicja Nowowiejska-Wiewiora; Lech Polonski
Journal:  Intern Emerg Med       Date:  2011-03-03       Impact factor: 3.397

5.  Reporting of quality indicators and improvement in hospital performance: the P.Re.Val.E. Regional Outcome Evaluation Program.

Authors:  Cristina Renzi; Chiara Sorge; Danilo Fusco; Nera Agabiti; Marina Davoli; Carlo A Perucci
Journal:  Health Serv Res       Date:  2012-03-30       Impact factor: 3.402

6.  Impact of ECG findings and process-of-care characteristics on the likelihood of not receiving reperfusion therapy in patients with ST-elevation myocardial infarction: results of a field evaluation.

Authors:  Kevin A Brown; Laurie J Lambert; James M Brophy; James Nasmith; Stéphane Rinfret; Eli Segal; Simon Kouz; Dave Ross; Richard Harvey; Sébastien Maire; Lucy J Boothroyd; Peter Bogaty
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

7.  Effectiveness of percutaneous coronary intervention within 12 hours to 28 days of ST-elevation myocardial infarction in a real-world Chinese population.

Authors:  Xingli Wu; Dingyou Yang; Yusheng Zhao; Caiyi Lu; Yu Wang
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

8.  Management of ST-segment elevation myocardial infarction in predominantly rural central China: A retrospective observational study.

Authors:  You Zhang; Shuyan Yang; Xinyun Liu; Muwei Li; Weidong Zhang; Haiyan Yang; Dayi Hu; Chuanyu Gao; Guangcai Duan
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.